Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The 254-bedded Aster Aadhar Hospital, Kolhapur is the city's most comprehensive multi-speciality hospital
The product will be marketed by Dr. Reddy's
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Construction of the plant will commence in 2025 with first production expected to be in 2027
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Subscribe To Our Newsletter & Stay Updated
